Biocardia Stock News

Virtu Financial LLC acquired a new stake in shares of BioCardia, Inc. (NASDAQ:BCDA) in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 33,264 shares of the companys stock, valued at approximately $132,000. Virtu Financial LLC owned about 0.20% of BioCardia as []

BioCardia, Inc. (NASDAQ:BCDA) CEO Peter Altman purchased 5,000 shares of the companys stock in a transaction that occurred on Thursday, November 18th. The shares were purchased at an average cost of $2.20 per share, for a total transaction of $11,000.00. The transaction was disclosed in a document filed with the SEC, which is available through []

SAN CARLOS, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a company focused on developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pu

The stock price of BioCardia Inc (NASDAQ: BCDA) increased by over 4% today. This is why it happened.

SAN CARLOS, Calif., Oct. 06, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (Nasdaq: BCDA), a company focused on developing cellular and cell derived therapeutics for the treatment of cardiovascular dise

SAN CARLOS, Calif., Sept. 10, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc.  [Nasdaq: BCDA], a company focused on developing cellular and cell derived therapeutics for the treatment of cardiovascular an

SAN CARLOS, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (Nasdaq: BCDA), today announced it has recorded a company presentation that will be available on demand at the H.C. Wainwright

SAN CARLOS, Calif., Aug. 13, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (Nasdaq: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease

SAN CARLOS, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,

BioCardia, Inc. (BCDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

SAN CARLOS, Calif., July 15, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc.  [Nasdaq: BCDA], a company focused on cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary

BCDA has candidate therapies that could potentially be curative of very prevalent heart diseases. The therapies have advanced to Phase 3 trials.

BioCardia, Inc. (BCDA) delivered earnings and revenue surprises of 14.29% and 31.43%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

BioCardia, Inc. (BCDA) delivered earnings and revenue surprises of 48.39% and -58.18%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

BioCardia has a leading-edge cardiac cell therapy platform. The company recently announced a settlement Term Sheet with Boston Scientific, BSX.